2023-507837-18-00
Recruiting
Phase 4
An open-label, multicenter, prospective, single-arm, exploratory study to assess role of pancreatic enzyme replacement therapy (PERT) (Creon® 25,000) in patients with Pancreatic Exocrine Insufficiency (PEI) after total gastrectomy.
BGP Products Operations GmbH19 sites in 3 countries60 target enrollmentStarted: January 15, 2025Last updated:
Overview
- Phase
- Phase 4
- Status
- Recruiting
- Sponsor
- BGP Products Operations GmbH
- Enrollment
- 60
- Locations
- 19
- Primary Endpoint
- Proportion of patients on stable dose of Creon, in whom there is no deterioration of nutritional status (as measured by no loss of body weight from baseline Visit).
Overview
Brief Summary
To evaluate the effect of Creon as PERT on the nutritional status of the patient with PEI developed post-gastrectomy.
Eligibility Criteria
- Ages
- 18 years to 65+ years (18-64 Years, 65+ Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male and female participants of any ethnic origin.
- •Participants between 18 to 80 (inclusive of both) years of age.
- •Willing to comply with the requirements of the study protocol.
- •Provide written informed consent.
- •Have previously undergone total gastrectomy.
- •Participant with pancreatic exocrine insufficiency as evidenced by clinical symptoms and confirmed by fecal elastase test.
- •Participant should not be receiving chemotherapy/radiotherapy during the last week prior to enrollment into the treatment phase.
- •Participant should not have exposure to any other investigational product within the last three months prior to enrollment into the treatment phase.
Exclusion Criteria
- •On treatment with medications like somatostatin or aprotinin that directly influence pancreatic exocrine function.
- •Anticipated non-availability for study visits/procedures.
- •Vulnerable subjects (such as persons kept in detention).
- •Previously taken Creon or any other PERT product within last 1 week prior to Day 1 of pretreatment phase.
- •Evidence of severe cardiovascular, respiratory, urogenital, gastrointestinal, hepatic, hematological, immunological, head, ears, eyes, nose, throat (HEENT), dermatological, connective tissue, musculoskeletal, metabolic (other than CF), nutritional, endocrine, neurologic, psychiatric disease; allergy, major surgery, or any other relevant disease as revealed by history or physical examination which might limit participation in or completion of the study.
- •History of allergic reaction or hypersensitivity to pancreatin or excipients of Creon.
- •Positive β-human chorionic gonadotropin (hCG) pregnancy test, established pregnancy, or breast-feeding at Day 1 of pretreatment phase. - Women of childbearing potential not using at least one effective method of contraception (preferably one whose effectiveness is not dependent on the user, such as an intrauterine device or implant).
- •Clinically relevant acute infections, febrile disease or any acute condition (illness) two weeks prior to Day 1 of pretreatment phase, as judged by the investigator.
- •History of alcohol or drug abuse within the last 2 years.
- •Lack of willingness to have personal study-related data collected, archived, or transmitted according to protocol.
Outcomes
Primary Outcomes
Proportion of patients on stable dose of Creon, in whom there is no deterioration of nutritional status (as measured by no loss of body weight from baseline Visit).
Proportion of patients on stable dose of Creon, in whom there is no deterioration of nutritional status (as measured by no loss of body weight from baseline Visit).
Secondary Outcomes
- Change in bodyweight from baseline
- Percentage of patients who develop symptomatic pancreatic exocrine insufficiency after gastrectomy.
- Symptoms of pancreatic exocrine insufficiency measured (as recorded in subject diaries)
- Nutritional parameters
- Gastrointestinal Quality of life index (GIQLI) questionnaire
- Treatment Emergent Adverse Events (TEAEs)
- Change in vital signs
Investigators
EUClinicalTrials@viatris
Scientific
BGP Products Operations GmbH
Study Sites (19)
Loading locations...
Similar Trials
Recruiting
Not Applicable
Effect of Protein Supplementation and Fluid Restriction on Plasma Sodium Levels in Patients Undergoing Pituitary SurgeryNCT07273630University Hospital, Basel, Switzerland282
Completed
Not Applicable
Preventive Nutritional Supplements for Preclinical PathologiesNCT07265115Centro de Edafología y Biología Aplicada del Segura21
Recruiting
Not Applicable
Effect of a Food Supplement on Blood Glucose Levels in Patients With Impaired Glucose ValuesNCT07263789Fondazione IRCCS Policlinico San Matteo di Pavia108
Completed
Not Applicable
ProIntens - Intensive Dietetic Care Pathwayondervoedingmalnutrition10003018NL-OMON49799Vrije Universiteit Medisch Centrum76
Not yet recruiting
Not Applicable
The Effect of Supplementary Foods Containing Trypsin, Chymotrypsin and Serratia Peptidase on Healing After Impacted Wisdom Tooth SurgeryNCT07269171Saglik Bilimleri Universitesi15